Background
• Surgical removal is generally recommended as the first step in treatment of mast cell tumors, but sometimes surgery is not possible due to the size or location of the tumor or due to financial limitations. In that situation, treatment with steroids, chemotherapy or targeted therapies such as Masitinib may be beneficial in controlling the disease. Masitinib has been conditionally approved by the FDA for use in dogs with certain mast cell tumors and this study is meant to further study how well the drug works.

Participation Requirements
• Dogs diagnosed with mast cell tumors that cannot be surgically removed or who decline to have the tumor surgically removed and who have not received treatment with chemotherapy or radiation therapy.

Procedures
• Physical examinations
• Tumor measurement and biopsy
• Blood, urine and bone marrow collections
• X-rays and ultrasound
• Treatment with Masitinib or placebo

Owner Responsibilities
• The study period lasts as long as the tumor is controlled by the study drug and can last up to a maximum of 2 years.
• Owners will be responsible for scheduling and keeping appointments every two weeks.
• Owners will need to give the provided drug or placebo orally every day.
• Owners will be responsible for keeping a study diary and reporting any side effects in a timely manner.

Benefits
• Many costs associated with screening tests to confirm eligibility are covered. Please call to discuss eligibility requirements further.
• The costs of all study visits, tests, and drugs are covered.
• If given Masitinib, the drug may help control or shrink the mast cell tumor.
• Results from this study may help other dogs with mast cell tumors in the future.